经营范围含中草药种植，地产中草药（不含中药饮片）购销，中草药收购，中药提取物生产（除依法须 经批准的项目外，凭营业执照依法自主开展经营活动） 企业名称于都县佑安中药材种植有限公司法定代表人刘怀军注册资本200万人民币国标行业制造业>医 药制造业>化学药品制剂制造地址江西省赣州市于都县贡江镇上欧工业园区齐民路193号3#楼企业类型 有限责任公司(国有控股)营业期限2025-12-2至无固定期限登记机关于都县市场监督管理局 来源：市场资讯 天眼查显示，近日，于都县佑安中药材种植有限公司成立，法定代表人为刘怀军，注册资本200万人民 币，由于都县佑安健康产业发展有限公司全资持股。 序号股东名称持股比例1于都县佑安健康产业发展有限公司100% ...

天眼查显示，近日，海南龙牛中药材有限公司成立，法定代表人为冀昌权，注册资本1000万人民币，由 扬子江药业集团江苏龙凤堂中药有限公司全资持股。 经营范围含许可经营项目：农作物种子经营；农作物种子进出口；药品进出口；国家重点保护野生植物 经营；采集（含采伐、移植）国家重点保护野生植物；药品生产；药品委托生产（不含中药饮片的蒸、 炒、炙、煅等炮制技术的应用及中成药保密处方产品的生产）；药品批发；药品零售（许可经营项目凭 许可证件经营）一般经营项目：蚯蚓养殖；地产中草药（不含中药饮片）购销；非主要农作物种子生 产；中草药种植；中草药收购；农产品的生产、销售、加工、运输、贮藏及其他相关服务；技术服务、 技术开发、技术咨询、技术交流、技术转让、技术推广；互联网销售（除销售需要许可的商品）（经营 范围中的一般经营项目依法自主开展经营活动，通过国家企业信用信息公示系统（海南）向社会公示） 企业名称海南龙牛中药材有限公司法定代表人冀昌权注册资本1000万人民币国标行业制造业>医药制造 业>化学药品制剂制造地址海南省三亚市崖州区崖州湾科技城高新区百泰产业园3号楼六层618室企业类 型有限责任公司（非自然人投资或控股的法人独资） ...

Core Insights - The capital market in Henan has effectively supported small and medium-sized enterprises (SMEs), with "Specialized, Sophisticated, and Innovative Loans" totaling over 39.3 billion yuan, leading to bank loans exceeding 224.4 billion yuan [1][2] - The "One Chain, One Policy, One Batch" initiative has facilitated financing of 26.582 billion yuan for chain enterprises, while investment roadshows have generated investment intentions of 7.612 billion yuan for 1,936 enterprises [1][3] - The establishment of a provincial "Specialized, Sophisticated, and Innovative" board has successfully listed 106 enterprises, providing a dedicated platform for capital market cultivation [1][3] Financing Support - The "Specialized, Sophisticated, and Innovative Loans" policy, which does not require fixed asset collateral, has been designed to meet the financing needs of high-tech SMEs, with a cumulative loan issuance of 39.395 billion yuan as of November 14, 2025 [2] - A risk compensation fund has been established by the provincial government to support these loans, ensuring a collaborative risk-sharing approach [2] - A comprehensive financial support network has been created, involving 54 banks and investment institutions, to provide extensive financing services [2] Market Access and Development - The Henan Provincial Department of Industry and Information Technology has been promoting the transformation of large-scale industrial enterprises into joint-stock companies, establishing a cultivation database of 545 companies [2] - The launch of the "Specialized, Sophisticated, and Innovative" board on September 16, 2025, marks a significant step in providing a dedicated capital market platform for SMEs [3] - The "One Chain, One Policy, One Batch" initiative has successfully facilitated financing for 11,418 chain SMEs, amounting to 26.582 billion yuan, enhancing their access to capital [3] Future Outlook - The capital market's targeted support has transformed the financing landscape for SMEs in Henan, moving from "difficult financing" to "easy financing" and enabling them to focus on growth [3] - Continued policy implementation is expected to further enhance capital market services for SMEs, solidifying the microeconomic foundation for high-quality local development [3]

每经头条（nbdtoutiao）——5年期大面积下线，3年期利率低至1.5%仍一单难求：要么"售罄"要么"额度 紧张"！中长期大额存单为何在消失？ （记者 曾健辉） 每经AI快讯，ST葫芦娃（SH 605199，收盘价：9.26元）12月1日晚间发布公告称，截至公告披露日，公 司及其控股子公司不存在对合并报表外单位提供担保的情况，公司累计为控股子公司担保余额约为3.13 亿元，占公司最近一期经审计净资产44.73%，无逾期担保情况。 2024年1至12月份，ST葫芦娃的营业收入构成为：医药制造业占比100.0%。 截至发稿，ST葫芦娃市值为37亿元。 ...

Core Viewpoint - The announcement by China Securities Index Co., Ltd. regarding the periodic adjustment of various indices, including the CSI 300, CSI 500, and others, indicates significant changes in the sample stocks effective after the market closes on December 12, 2025 [1]. Group 1: Index Adjustments - The CSI 300 index will replace 11 sample stocks, while the CSI 500 will replace 50 stocks, and the CSI 1000 will replace 100 stocks [1]. - The CSI A50 index will see 4 stocks replaced, the CSI A100 will replace 6 stocks, and the CSI A500 will replace 20 stocks [1]. Group 2: Company-Specific Information - Tai Chi Group (600129.SH) is listed among the stocks being removed from the CSI A500 index [3]. - The company has been identified in a price risk governance notice issued by the Tianjin Municipal Medical Procurement Center, which requires companies to self-check and adjust drug prices to reasonable levels [3]. - Several products from Tai Chi Group's subsidiaries are included in a list of drugs with prices exceeding three times the minimum daily cost of similar drugs, which may lead to regulatory actions [3][4]. Group 3: Company Background - Tai Chi Group, established in 1979 and located in Chongqing, primarily engages in the pharmaceutical manufacturing industry [4]. - The company has a registered capital of 55,689.0744 million RMB and a paid-in capital of 16,684.2 million RMB [4].

Group 1: PMI Performance - The national manufacturing PMI for November recorded at 49.2%, a slight increase of 0.2 percentage points from the previous month, but still 0.9 percentage points below the median of the past five years[3] - The new orders index rose to 49.2%, up 0.4 percentage points from last month, indicating a recovery in demand[5] - The production index reached 50.0%, increasing by 0.3 percentage points, returning to the growth threshold[5] Group 2: Export and Demand Improvement - The new export orders index significantly rebounded to 47.6%, up 1.7 percentage points from last month, reflecting resilience in exports[5] - Tariff reductions from recent US-China trade talks are expected to provide a short-term boost to export demand, similar to previous tariff easing events[4] - The manufacturing purchase price index rose to 53.6%, up 1.1 percentage points, indicating upward pressure on PPI[19] Group 3: Construction and Non-Manufacturing Sector - The construction industry business activity index increased to 49.6%, up 0.5 percentage points, although it remains below the growth threshold[6] - The construction new orders index rose to 46.1%, marking the second highest level this year[6] - The non-manufacturing business activity index fell to 49.5%, down 0.6 percentage points, indicating a decline in service sector activity[25] Group 4: Risks and Economic Outlook - Risks include unexpected changes in fiscal and monetary policy, macroeconomic data, and external factors such as tariffs[7] - Infrastructure investment is anticipated to accelerate in the fourth quarter as a key driver for achieving growth targets[4]

声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 国家知识产权局信息显示，北京胡曼智造科技有限责任公司、南京胡曼智造科技有限公司取得一项名 为"运动系统及全自动检验仪器"的专利，授权公告号CN116256529B，申请日期为2023年2月。 天眼查资料显示，北京胡曼智造科技有限责任公司，成立于2021年，位于北京市，是一家以从事医药制 造业为主的企业。企业注册资本200万人民币。通过天眼查大数据分析，北京胡曼智造科技有限责任公 司共对外投资了2家企业，参与招投标项目27次，财产线索方面有商标信息39条，专利信息53条，此外 企业还拥有行政许可3个。 南京胡曼智造科技有限公司，成立于2022年，位于南京市，是一家以从事科技推广和应用服务业为主的 企业。企业注册资本820.7047万人民币。通过天眼查大数据分析，南京胡曼智造科技有限公司共对外投 资了3家企业，专利信息26条，此外企业还拥有行政许可8个。 ...

Group 1 - The core point of the article is that Hualan Biological Engineering Co., Ltd. announced the convening of its sixth board meeting to discuss the management system for senior management compensation and performance assessment [1] - For the first half of 2025, Hualan's revenue composition shows that the pharmaceutical manufacturing industry accounts for 99.07% of its total revenue, while other businesses contribute 0.93% [1] - As of the report date, Hualan's market capitalization is 8 billion yuan [1]

每经头条（nbdtoutiao）——已有75人遇难，1名死者为消防员，还有10名消防员受伤！记者现场直击香 港大埔火灾：燃烧的宏福苑，五级大火的五个谜团 （记者 曾健辉） 每经AI快讯，科源制药（SZ 301281，收盘价：29.28元）11月28日晚间发布公告称，公司第四届第十五 次董事会会议于2025年11月28日在公司会议室召开。会议审议了《关于终止发行股份购买资产并募集配 套资金暨关联交易事项并撤回申请文件的议案》等文件。 2025年1至6月份，科源制药的营业收入构成为：医药制造业占比100.0%。 截至发稿，科源制药市值为32亿元。 ...

北京市统计局数据显示，1-10月，全市规模以上工业企业实现营业收入26462.2亿元，同比增长6.7%； 实现利润总额1613.2亿元，同比增长1.5%。分登记注册类型看，内资企业实现利润总额993.8亿元，同 比增长17.5%；外商及港澳台投资企业实现利润总额619.4亿元，同比下降16.8%。分规模看，大中型企 业实现利润总额1330.6亿元，同比下降1.6%。分行业看，在37个工业行业大类中，21个行业利润同比增 长，2个行业亏损减少。其中，电力、热力生产和供应业实现利润总额418.0亿元，同比下降2.5%；汽车 制造业实现利润总额212.2亿元，同比增长11.7%；计算机、通信和其他电子设备制造业实现利润总额 298.1亿元，同比增长3.7%；医药制造业实现利润总额137.8亿元，同比下降13.8%；专用设备制造业实 现利润总额102.2亿元,同比增长16.5%。截至10月末，规模以上工业企业应收账款6686.0亿元，同比下降 12.6%；产成品存货1644.9亿元，同比增长2.5%。 （文章来源：第一财经） ...